Background
Worldwide, glaucoma results in irreversible blindness in humans, especially in elderly individuals, and is associated with oxidative stress [1] . One of the critical risk factors of primary open-angle glaucoma (POAG) is ocular hypertension [1] . Recent studies have shown that oxidative stress is involved in the occurrence and development of POAG [2, 3] . In conditions of oxidative stress, the biological defense system comes across dysfunctions and will cause an imbalance between the production and elimination of reactive oxygen species (ROS) [4, 5] . Increased accumulation of ROS leads to damages to genes, proteins, and lipids [6] . These effects of oxidative stress have also been reported in corneal disease [7] , cataract [8] , retinal disease [9] , and glaucoma [10] .
According to the mechanical theory of glaucoma, studies have shown that outflow of the aqueous humor may be partially blocked by dysfunction induced by oxidative stress of trabecular meshwork cells, which results in ocular hypertension [11] . Pathologically high intraocular pressure (IOP) can further cause retinal ganglion cell mitochondrial dysfunction and apoptosis and contributes to loss of vision in patients with glaucoma [12] .
Recently, the roles of nuclear factor erythroid 2-related factor 2 (Nrf2) and the associated signaling pathways in the regulation of oxidative stress responses have been studied [13, 14] . Nrf2 is an important regulator of protective antioxidant and anti-inflammatory responses, which regulates the expression of many genes [15] . Nrf2 regulates not only responsive antioxidant enzymes but also a series of genes involved in processes that include inflammation, tissue remodeling, and fibrosis [16] . The Nrf2 signaling system, together with its regulatory molecules and interacting proteins, performs a critical antioxidant and anti-inflammatory function in cells. In normal conditions, Nrf2 is located in the cytoplasm and mediates proteasome degradation by binding to Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1).
Following the initiation of cellular oxidative stress on exposure to electrophiles, including hydrogen peroxide (H 2 O 2 ) superoxide anion (O 2 -), hydroxyl radical (-OH), and ROS, Keap1 undergoes conformational changes. These changes allow Nrf2 to be transported into the cell nucleus to bind to the antioxidant response element (ARE) regions. Then, transcription of antioxidant enzymes and phase II detoxification enzymes occurs, including heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase 1 (NQO1) [17] . Also, g-glutamyl cysteine ligase catalytic subunit (GCLC), glutathione peroxidase [13] , glutathione-S-transferase (GST), catalase, superoxide dismutase, and thioredoxin uridine 5'-diphospho-glucuronosyltransferase) (UDP)-glucuronosyltransferase occurs [18] [19] [20] [21] . However, Nrf2 may be dissociated from the cytoplasmic Nrf2-keap1-cul3 complex by p62, which is a marker of cell autophagy [22] . Some compounds, primarily exogenous compounds, including polyphenols [23] , flavonoids [24] , terpenoids [25] , or noncoding RNAs [26] have been reported to be Nrf2 activators or inducers. These compounds may have key roles in protecting ocular cells from oxidative stress, inflammation, and fibrosis [27, 28] . The participation in the mechanism and antioxidative capacity of Nrf2 occurs in several systemic diseases, including respiratory disease [29] , cardiovascular, and cerebrovascular disease [30] , degenerative disease, tumors [31] , and ocular disease.
This review aims to focus on the specific role and potential mechanism of Nrf2-mediated defense in glaucoma, including the prevention of oxidation and fibrosis in glaucoma. Publications have been reviewed from the past 20 years, between 1999 and 2019, with a focus on the potential mechanisms of Nrf2 in the occurrence and development of glaucoma and the prognosis following surgical treatment. Also, several factors that induce the expression of Nrf2 in trabecular meshwork cells, retinal ganglion cells, and Tenon's capsule fibroblasts are discussed.
Oxidative Stress, Glaucoma, Trabecular Meshwork Cells, and Nrf2
The trabecular meshwork is an avascular, complex connective tissue component that can effectively regulate the outflow of aqueous humor [32] . The sources of trabecular meshwork oxidative stress include ultraviolet (UV)-based byproducts of the anterior chamber, excess ROS accumulation [33] , and the imbalance between oxidants and antioxidants [6, 34] . Studies have shown that in patients with POAG, the trabecular meshwork is exposed to ROS in aqueous humor, which suggests that ROS may have a causative role in glaucoma at the level of trabecular meshwork cells [35, 36] . As one of the most sensitive ocular cells, the trabecular meshwork cell is a primary cell type that occupies and forms the proximal portion of the aqueous humor outflow pathway. Trabecular meshwork cells under oxidative stress show changes that are typical for POAG. These changes include the accumulation of extracellular matrix (ECM), cell apoptosis, cell necrosis, changes in the structure and function of the cytoplasm and lysosomes [37] , and disruption of the cytoskeletal disruption [38] . These changes may be significantly reduced using prostaglandin analogs [39] , antioxidants, beta-blockers [40] , or the local use of carbonic anhydrase inhibitors [41, 42] .
The reduction of total reactive antioxidant capacity in patients with POAG is reduced by 60-70%, which indicates that these patients might be more susceptible to damage from oxidative stress [6, 43] . In 2017, Cheng et al. found that compared with normal human trabecular meshwork cells, Nrf2 expression was down-regulated in glaucomatous trabecular meshwork cells, e921514-2 and in both cell types, the overexpression of Nrf2 promoted cell viability and reduced cell apoptosis [44] . Also, in 2016, Wang et al. showed that microRNA-93 (miRNA-93) inhibited the cell viability and induced apoptosis of the glaucomatous trabecular meshwork cells via the suppression of Nrf2 [45] . These findings support the role of Nrf2 in protecting trabecular meshwork cells from oxidative stress.
Oxidative Stress, Glaucoma, Retinal Ganglion Cells, and Nrf2
Retinal ganglion cells are specialized neurons that receive visual information from photoreceptor cells [46] . Retinal ganglion cells transmit visual information to the brain in the form of retinal action potentials [9] . In many ocular diseases, including glaucoma, age-related macular degeneration, and diabetic retinopathy, oxidative stress results in cell death of retinal ganglion cells [9, 27] .
The potential mechanisms involved in cell death of retinal ganglion cells in glaucoma and disorders of optic nerve blood flow have been studied [47] . These mechanisms include excitatory glutamate toxicity [48] , and injury due to the effects of nitric oxide [49] . Recently, studies have shown that vascular and mechanical processes that include pro-apoptotic factors can result from oxidative stress leading to oxidative mitochondrial dysfunction in retinal ganglion cells and apoptosis during acute glaucoma [50] [51] [52] .
Based on the vascular theory of glaucoma, reactive oxygen species (ROS) are produced by ischemia. The mechanical theory of glaucoma proposes that ROS formation results from increased intraocular pressure (IOP) and inhibition of axons of retinal ganglion cells [53] . Chronic hypertensive glaucoma and retinal ischemia caused by a sudden increase in IOP stimulate the production of ROS and dysregulate essential autophagy [50] . With a chronic retinal injury or a sudden and severe increase in IOP, cell autophagy increases that result in retinal ganglion cell death in a relatively short time [50] . Also, in the retina of humans with ocular hypertension, several proteins are involved in redox homeostasis in cells, and oxidative stress responses are upregulated [54] .
In 2015, Xu et al. reported that Nrf2 had a role in retinal neuroprotection from ischemia-reperfusion injury [55] . These investigators developed and studied an Nrf2 knockout mouse retinal ischemia-reperfusion model [55] . When compared with wild-type mice, the loss of neurons in the retinal ganglion cell layer in the Nrf2 knockout mice was increased, and the retinal ganglion cell activity of Nrf2 knockout mice was reduced, indicating that Nrf2 had an inherent protective effect on retinal ganglion cells [55] . In 1999, Lam et al. showed that, in a rat model, repeated mild retinal reperfusion resulted in chronic oxidative stress, especially in cell mitochondria [56] . Virusmediated delivery of Nrf2 can effectively protect retinal ganglion cells from damage due to oxidative stress after acute nerve damage [57] . Therefore, pharmacologic and physiological induction of Nrf2 has potential as a new therapeutic strategy for retinal ischemia-reperfusion damage, and possibly for other retinal diseases, including glaucoma.
Fibrosis, Nrf2, and Tenon's Capsule Cells
Fibrosis is part of the healing process that follows inflammation in many diseases, including lung disease, liver fibrosis [58] , systemic sclerosis [59] , and diabetic renal fibrosis [60] . The mechanisms leading to fibrosis can involve stress responses involving the endoplasmic reticulum (ER) [61] , oxidative stress [62] , and inflammation [63] . Trabeculectomy, a traditional method of glaucoma filtration surgery, is regarded as one of the most effective strategies to achieve a sustained reduction in IOP in patients with glaucoma [64] . Glaucoma filtration surgery destroys the structure of the conjunctiva and subconjunctival tissue, activates the immune system, and results in the release of inflammatory cytokines [65] . Platelet activation and inflammatory cytokines activate downstream vascular endothelial growth factor-α (VEGF-α), transforming growth factor-b (TGF-b), and platelet-derived growth factor (PDGF) [65] . Inflammatory cytokines and growth factors induce cell proliferation, cell migration, the accumulation of extracellular matrix (ECM), and results in the contraction of collagen to promote scar formation, which results in impaired surgical outcomes in patients with glaucoma [66] .
TGF-b1 causes cell apoptosis [67] , the expression of genes associated with fibrosis, and myofibroblast differentiation following the production of ROS [68] . TGF-b1 also inhibits the glutathione antioxidant system [69] . The miRNA-29 family is closely associated with TGF-b-mediated fibrosis [70, 71] . In patients with glaucoma, TGF-b2 was shown to stimulate fibroblast proliferation in Tenon's capsule by the suppression of miR-29b expression regulated by Nrf2 [72] . These findings indicate that Nrf2 may protect cells from the effects of TGFb and fibrosis by upregulating miR-29b. Long noncoding RNA (lncRNA)-MEG3 upregulates the expression of Nrf2 and controls the proliferation of ECM [73] . These findings support that Nrf2 might be a potential therapeutic target to prevent fibroblast proliferation in Tenon's capsule after glaucoma filtration surgery. L2H17, a chalcone analog RGCs A synthetic compound L2H17 exhibits antioxidative effects by activating the Nrf2 pathway [110] Chlorogenic acid RGCs In food or food supplements Reduces oxidative injury through IncRNA-TUG1/Nrf2 [111] processes by targeting genes [6] . Long noncoding RNAs (ln-cRNAs) are >200 nucleotides in length that regulate transcription (cis or trans), the organization of nuclear domains, and RNA or protein formation through several different mechanisms [6, 74, 75] . Recently, noncoding RNAs have become a focus of glaucoma research, as shown in Table. 1. Noncoding RNAs provide a potential therapeutic approach for defense against oxidative stress and fibrosis in glaucoma.
Novel Strategies for

Novel Strategies for Activating Nrf2: Exogenous Compounds
There are several compounds that have anti-inflammatory, antioxidant, and properties that prevent fibrosis by directly targeting the Nrf2 and Nrf2 inhibitors that include Keap1, Bach1, c-Myc, with the potential for preventing ocular disease [76] [77] [78] . There has been increasing interest in studies on the role of exogenous compounds to prevent oxidative stress. Compounds that include chalcones, flavonoids, and terpenoids can suppress Nrf2 ubiquitination and induce ARE-mediated antioxidative and cytoprotective enzymes [79] . These proteins react with the cysteine thiolate groups in Keap1, which are typical Nrf2 inducers [79] . Also, phenols and quinones, such as t-BHQ [80] , polyphenolic flavonoids, including quercetin [81] , stilbenoid, and nonflavonoid polyphenolics, including resveratrol [82] have been studied. Other compounds include sulforaphane (SFN), sphaeropsidin A (SA), CDDO-Im, long-acting (1R)-isopropyloxygenipin (IPRG001), omaveloxolone, astaxanthin [83] , and lycopene [84] , which also show activation of Nrf2 and upregulation of some downstream Nrf2 genes. Table 2 summarizes the studies on Nrf2 activators associated with glaucoma and neuroprotection.
The Negative Effects of Nrf2 in Glaucoma
Although Nrf2 has many protective effects in oxidative stress, studies have shown that Nrf2 can have harmful effects, including as a carcinogen, as cancer-associated mutations activate Nrf2 [85] [86] [87] . Also, when ROS exceeds the critical threshold, Nrf2 upregulates the expression of Klf9. However, Klf9 inhibits Trx reductase expression, amplifying the ROS cascade, which ultimately leads to cell death [88] . Therefore, it is important to consider the beneficial effects of Nrf2 as well as the harmful effects.
Conclusions
In the past 20 years, studies have shown that Nrf2 has a role in the occurrence and development of glaucoma and the prognosis following surgical treatment. Also, several factors that induce the expression of Nrf2 in trabecular meshwork cells, retinal ganglion cells, and human Tenon's capsule fibroblasts. Nrf2 plays a specific role in the occurrence and development of glaucoma. Oxidative stress accounts for some of the main mechanisms of trabecular meshwork cell injury, apoptosis, aqueous humor outflow disorders, and the loss of structure and function of retinal ganglion cells. Also, Nrf2 has a role in preventing fibrosis after glaucoma filtration surgery. Therefore, Nrf2 might be a potential therapeutic target to protect ocular cells from oxidative stress.
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